Aktienanalyse zu Madrigal Pharmaceuticals Inc (MDGL)MDGLMadrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Madrigal Pharmaceuticals appears to be a good buy right now due to its strong sales growth momentum, with Rezdiffra achieving $364.3 million in Q2, a 71% year-over-year increase, and a current price of $471.75, significantly below analyst targets ranging from $605 to $964. The RSI is at 10.336, indicating the stock is oversold, which could present a buying opportunity. However, the main risk is the high forward P/E of 78.125, suggesting that the stock is priced for significant future growth, which may not materialize if clinical trials do not yield positive results.

3 analysts cover MDGL: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 636.22.